COVID-19 Booster Study In Immunocompromised Patients Gives Novavax Another Shot On Goal
Manufacturing Issues Have Delayed Filing
While delays to manufacturing have frustrated the vaccine’s submission, Novavax is still confident its nanoparticle-based jab will play a significant role in COVID-19.
You may also be interested in...
Japan approves a second antibody therapy for COVID-19 in short order, while India gives the go-ahead to a local clinical program for Novavax/Serum Institute's recombinant protein vaccine candidate.
A third death has been reported in Japan following dosing with Moderna's mRNA vaccine and while an investigation is underway, it is not seen as product-related. Takeda has also signed a production and supply deal with Japan's government for Novavax's nanoparticle vaccine.
Moderna may benefit from data indicating strong efficacy against the Delta strain, though an analyst pointed out that they come with some important caveats.